Featured Research

from universities, journals, and other organizations

New Pill Is Better Than Traditional Chemotherapy, Study Suggests

Date:
October 8, 2007
Source:
University of Leeds
Summary:
A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease. The oral chemotherapy drug offers fewer side-effects and less time in hospital -- and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy.

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

"Standard chemotherapy can be incredibly disruptive to people's lives," said Prof Professor Chris Twelves of the University of Leeds, who led the research. "Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course -- and the side effects can be unpleasant."

The oral chemotherapy drug Xeloda (capecitabine) offers fewer side-effects and less time in hospital -- and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).

The research showed that about 71 percent of patients given Xeloda were still alive after five years, compared to 68 percent of patients treated with standard chemotherapy injections.

Prof Twelves's study followed 1,987 patients who had undergone colon cancer surgery. It found that patients treated with Xeloda spent 85 percent less time with their doctor or at the hospital, and experienced fewer side effects. The new results, showing patients' five-year survival rates, confirm the effectiveness of the treatment.

"We now have long-term evidence now that clearly supports Xeloda's superiority over the Mayo Clinic regimen," said Prof Twelves. "There is now no reason why we should ask colon cancer patients to endure the burdens associated with that older treatment."

Xeloda is manufactured by Roche Holding AG, the world's biggest maker of cancer medicines. The study's initial results helped the Swiss-based company win European and US approval in 2005 for using Xeloda to treat colon cancer after surgery. The medicine also is cleared for breast tumours, and in March Roche won European approval for its use with chemotherapy in people with advanced stomach cancer.

About 945,000 new cases of colorectal cancer are diagnosed each year globally, and the disease is responsible for about 492,000 deaths, according to Roche. The cancer is curable when caught early.

The new results show patients' five-year survival rates. An earlier report from the study, Capecitabine as Adjuvant Treatment for Stage III Colon Cancer, was published in the New England Journal of Medicine (N Engl J Med 352;26) on June 30, 2005.


Story Source:

The above story is based on materials provided by University of Leeds. Note: Materials may be edited for content and length.


Cite This Page:

University of Leeds. "New Pill Is Better Than Traditional Chemotherapy, Study Suggests." ScienceDaily. ScienceDaily, 8 October 2007. <www.sciencedaily.com/releases/2007/10/071008103247.htm>.
University of Leeds. (2007, October 8). New Pill Is Better Than Traditional Chemotherapy, Study Suggests. ScienceDaily. Retrieved August 31, 2014 from www.sciencedaily.com/releases/2007/10/071008103247.htm
University of Leeds. "New Pill Is Better Than Traditional Chemotherapy, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/10/071008103247.htm (accessed August 31, 2014).

Share This




More Health & Medicine News

Sunday, August 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins